SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced that David A. Ramsay, Halozyme’s CFO will present at the Roth Capital Partners 21stAnnual Growth Stock Conference on Tuesday, February 17, 2009 at 4:00 p.m. PST (7:00 p.m. EST) at the Ritz-Carlton Laguna Niguel in Dana Point, California.
